FunPep Company Limited engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices in Japan and internationally. The company develops SR-0379, a functional peptide which is in Phase III clinical trial for the treatment of skin ulcer; FPP003, an antibody-inducing peptide which is in Phase II clinical trial for the treatment of psoriasis and ankylosing spondylitis; FPP004X, an antibody-inducing peptide which is in Phase I clinical trial for the treatment of pollinosis; and FPP005, an antibody-inducing peptide which is in pre-clinical trial stage for the treatment of psoriasis. It is also involved in the development of Curepeptin, an antimicrobial peptide that disrupts bacterial cell membranes. The company was incorporated in 2013 and is headquartered in Ibaraki, Japan.
Frequently asked questions
What sector does FunPep Company Limited (4881) operate in?
FunPep Company Limited belongs to the Healthcare sector and operates in the Biotechnology industry.
What is FunPep Company Limited (4881) current stock price?
As of the latest data, FunPep Company Limited stock price is ¥49, with a previous close of ¥49.
What is FunPep Company Limited (4881) current market capitalization?
FunPep Company Limited market cap is approximately 2.20 billion.
What is FunPep Company Limited (4881) Earnings Per Share (EPS)?
The trailing EPS is -¥50.
What is FunPep Company Limited (4881) EBITDA?
FunPep Company Limited EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -293.80 million.
Does FunPep Company Limited (4881) pay dividends?
No. FunPep Company Limited does not pay a dividend.
What is FunPep Company Limited (4881) beta (volatility) score?
FunPep Company Limited has a beta of 0.809, meaning its volatility is roughly in line with the market.
